IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL et al.

Examiner:

Kamal A Saeed

Application No.: 10/073,160

Art Unit:

1626

Filed:

February 13, 2002

as Pharmaceuticals

TELEFAX CERTIFICATE

Title:

Acylated Indanyl Amines and Their Use

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at \$71-273-0025, on

Date of Transmission

Mail Stop: Petition Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450 FAX RECEIVED

OCT 1 2 2006

OFFICE OF PETITIONS

PETITION TO WITHDRAW APPLICATION FROM ISSUE UNDER 37 C.F.R. § 1.313(c)(2); AND REQUEST FOR CONTINUED EXAMINATION

Dear Sir:

Pursuant to 37 C.F.R. § 1.313(a), Applicants hereby petition for the withdrawal of the above-identified application from issue, and include the requisite fee of \$130.00 under 37 C.F.R.§ 1.17(h). Applicants submit that withdrawal from issue is required to ensure proper consideration and acknowledgement by the Examiner, on the record, of related applications to the instant application. A good faith attempt was made to bring the aforementioned related applications to the attention of the Examiner in a paper submitted on October 19, 2005, at page 17, of Applicants' response (Applicants' remarks attached as Appendix A). Applicants in conducting a last check of the instant application before issuance realized that Examiner's response had failed to indicate that said related applications had been considered.

In support of Applicants' petition, concurrently filed herewith is a Request for Continued Examination (RCE), as required under 37 C.F.R. § 1.313(c)(2), that includes requisite fee of \$790.00 and an Information Disclosure Statement (IDS) (submission) listing the related applications to have such related applications properly considered and

10/13/2006 CKHLOK

acknowledged on the record. 00000006 181982 10073160

01 FC:1464

130.00 DA

Information Disclosure Statement (IDS)

Applicants submit herewith an IDS to request on-record acknowledgement and consideration the listed applications that include similar subject matter (i.e., are in the same technical field) as the instant patent application.

If there are any issues that can be resolved by a telephone conference or an Examiner's amendment, the Examiner is invited to call the undersigned attorney at (908) 231-3115.

The Commissioner is hereby authorized to charge the fee required and any additional fees that may be needed to Deposit Account No. 18-1982 in the name of Aventis Pharmaceuticals Inc.

Dated: October 12, 2006

Robert J. Kajubi

Registration No. 55,312 Attorney for Applicants

Respectfully submitted,

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800

Telephone: 908-231-3410 Telefax: 908-231-2626

Docket No. DEAV2001/0004 US NP

Linder the Co.	nonuedo	Dadudlan set -2 ces	•		U.S. R	Patent and	vonqqA zmebant	ed for us	through 07/31/2008, OMB 0651-0031; U.S. DEPARTMENT OF COMMERCE
Application Number						10/073,160			
TRANSMITTAL				Filing Date	February 13, 2002 0CT 1 9, 2000				
FORM				First Named Inve	Hartmut STROBEL et al.				
				Art Unit	1624 OFFICE OF PETITIONS				
(to be used for all correspondence after initial filing)				Examiner Name	Kamal A Saeed				
Total Number of	Attorney Docket	Number	DEAV2001/0004 US NP 1						
ENCLOSURES (Check all that apply)									
Fee Trans	millal F	orm		Drawing(s)				After	Allowance Communication to TC
☐ Fe	Fee Attached			Licensing-related Papers				Appe of Ap	eal Communication to Board peals and interferences
Document(s) Reply to Missing Parts/		Rema * PETI UNDER	TION TO WITHDRAY R 37 C.F.R. § 1,313(EQUEST FOR CON	ATION FROM ISS		Appe (Appe Propr Statu Other below Requ 1449	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Request for Continued Examination 1449 form		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
	sanof	aventis U.S. LLC	C					,	
Signature Total Fejuh'									
Printed name Robert J. Kajubi									
Date October 12, 2006		Reg. I				g. No. 55,312			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in									
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USPTO FAX NO. 572-273-0025 ; Total No. of Pages Transmitted: 11									
Signature , Total No. of Pages Transmitted: 11									
Typed or printed name		Paul Irvine						Date	October 12, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, is hould be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.